BCL2L1 and glioblastoma: Specifically, as previously observed, pladienolide B treatment significantly downregulated the anti-apoptotic Bcl-xL variant while upregulated the pro-apoptotic Bcl-xS variant in intact (non-transfected) GBM cells (Fig. 9m).